Big pharma snub, lack of placebo to blame for lack of medical pot research: experts

Despite a growing number of Canadians turning to medical cannabis

A disinterested pharmaceutical industry and the conundrum of finding a convincing placebo are just two reasons experts say there has been little quality research into medicinal marijuana.

A growing number of Canadians are turning to medical cannabis despite questions about its risks and effectiveness as a health product.

Marijuana’s unconventional journey onto the medical market puts it at odds with more mainstream medications, which typically undergo years of costly scrutiny before being approved for use, said Mark Ware, a pain researcher at McGill University Health Centre in Montreal.

Ware said pharmaceutical companies are willing to pay hundreds of millions of dollars for clinical trials because once a drug is approved they have a window of time to sell it exclusively.

“When you think about medications that have been given approval to be sold in pharmacies, that’s where most if not all of our medications come from,” he said.

“That model simply does not hold for much of the classical herbal cannabis research, where you’re looking for basic claims of efficacy and safety, but not trying to make a formal claim for a product that is going to be patented.”

READ: Marijuana rules will be ‘a work in progress’

Ware, who also served as vice-chair on the federal government’s task force on legalizing cannabis, said competition among licensed marijuana producers is leading some of them to funnel money toward research in an effort to differentiate their brand from others.

But Dr. Mike Allan, a professor of family medicine at the University of Alberta in Edmonton, said there are few benefits for producers to conduct the research.

“It’s already at market so there’s really no incentive, or virtually no incentive, for licensed producers to take the money they’re generating from the sale of these products and reinvest it in research,” Allan said.

While a positive outcome might not have much of an effect on the industry’s bottom line, a negative outcome could seriously harm profits, he added.

Data from Health Canada show the number of clients registered with licensed medicinal cannabis producers jumped between June 2016 and June 2017, from 75,166 to more than 200,000. Registrations more than tripled in each of the two previous years.

University of Saskatchewan professor, Robert Laprairie, said the absence of the pharmaceutical industry means medical marijuana research is being done for the benefit of the patient.

“We’re in a unique place because a lot of large pharmaceutical companies are reluctant to fund these studies where they don’t necessarily see the incentive for something that they aren’t able to patent,” said Laprairie, who conducts cannabinoid research at the university.

WATCH: Province, Feds see lots of work ahead of marijuana legalization

Laprairie said he has seen a heavy push in recent months from academics, patients and licensed producers for more medical cannabis research.

But Dr. Meldon Kahan of the Women’s College Hospital in Toronto, said this kind of research, sponsored by licensed producers, is still problematic.

“You can design a short-term study with marijuana, or for that matter, with alcohol or opiates, and say, ‘Look, we gave people a bunch of alcohol over a three-day period or one week or one month and they seem to feel better. It helped their anxiety.’ But that doesn’t mean it’s a good medication,” he said.

Kahan said there does appear to be some evidence that cannabidiol, a compound in marijuana, does have some medical benefits, including pain relief, but more study is needed.

Ware said another dilemma in conducting research on medical marijuana is the absence of a plausible placebo, especially because study participants often have experience using cannabis and recognize if they have been placed in the study or control group.

“Access to a credible placebo may seem like an odd thing to have as a challenge,” Ware said.

“But bear in mind that many of these studies are placebo-controlled, so you need a drug which is a credible placebo — looks and smells and for all intents and purposes pretends it is cannabis when in fact it does not have the active ingredient you are testing.”

Allan cited a study that found between 85 and 90 per cent of nurses could tell when patients were on pills derived from cannabis.


@katslepian

katya.slepian@bpdigital.ca

Like us on Facebook and follow us on Twitter.

Get local stories you won't find anywhere else right to your inbox.
Sign up here

Just Posted

Officials won’t say how crowded Fraser Valley hospitals would deal with patient surge

Amid coronavirus case and crowding issues, health officials won’t say where more patients would go

Sasquatch Montain Aussie Day celebration raises $800

Proceeds of bikini runs, toonie tosses and more go to wildfire victims

Abbotsford Police issue 81 speeding tickets in school zones over 2 days

‘30 in 30’ traffic-enforcement blitz took place last Thursday and Friday

Salvation Army kettle campaign raises $121,000 in Abbotsford

Christmas fundraising up $20,000 over previous year

DNA confirms SUV struck and killed Abbotsford cyclist in 2015, court hears

Kerry Froese operated company that owned vehicle that struck and killed Ronald James Scott in 2015

B.C. reports first coronavirus in Vancouver region

First patient visited Wuhan, China, reported symptoms

Opioid crisis to blame for shorter life expectancy in B.C. men, says Stats Can

Opioid crisis held responsible for declining life expectancy

Earthquake on top of highway closure a wake up call for Island’s West Coast

“When someone says, ‘Be prepared for 72 hours,’ that means exactly that: be prepared.”

Newspapers, hockey cards discovered in Mission school’s forgotten time capsule

Capsule opened in front of students from West Heights Community School

Pregnant B.C. woman stuck in Wuhan, the epicentre of coronavirus outbreak

Woman is due to give birth in Wuhan, China unless she can get out

Taxi association asks B.C. Supreme Court to stop Uber, Lyft from operating

Petition alleges Passenger Transportation Board did not take taxis into account

Majority of Canadian boards had no female members in 2016 and 2017: StatCan

Statistics Canada says 18.1 per cent of director seats were held by women in 2017

Swapping grape varieties can help winemakers adapt to climate change: UBC study

Report says 56% of wine-grape-growing regions would be lost if global climate warms by 2 C

Alberta premier wants feds to approve Teck mine for benefit of First Nations

Kenney: ‘Surely [reconciliation] means saying yes to economic development for First Nations people’

Most Read